Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07699445

The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar Depression

This research study examines how a medication called lumateperone may affect mood symptoms, and inflammation in adults with bipolar disorder over approximately 6 weeks. An MRI scan to calculate biological age of the brain will also be obtained at the start of the study.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location contact

Michael E Henry, MD

CONTACT

[email protected]

6176435750

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 to 65 years.
  • Meets DSM-V criteria for Bipolar I Disorder -Depressed without psychosis as confirmed by a semi-structured clinical interview that includes the Mini International Neuropsychiatric Interview.
  • Current episode at least 4 weeks in duration but not longer than 12 months.
  • Depression score > 20 on the Montgomery Asberg Depression Rating Scale (MADRS).
  • BMI > 30
  • Capable of providing informed consent.

Exclusion criteria

  • Meets DSM-V criteria for Schizophrenia, Schizoaffective disorder, or has significant mood-incongruent psychotic symptoms.
  • Young Mania Rating Scale score >12.
  • Meets DSM-V criteria for rapid cycling.
  • Co-Morbid psychiatric illness, other than generalized anxiety and specific phobias, that in the opinion of the investigator is severe enough that it would likely interfere with the interpretation of changes in the subject's mood state.
  • Meets DSM-V criteria for an active substance use disorder within the past month.
  • Active medical condition that in the opinion of the investigator would contribute to the subject's depressed mood (e.g. hypothyroidism).
  • Significant risk of suicide or self -harm as assessed by clinical interview and the Columbia Suicide Severity Rating Scale (C-SSRS).
  • Significant risk of harm to others as assessed by clinical interview.
  • Pregnancy, or, in women of child-bearing potential, an unwillingness to use an accepted method of birth control for the duration of the study.
  • Current or prior treatment with lumateperone.
  • Moderate or severe hepatic impairment.
  • Current treatment with strong or moderate CYP3A4 inhibitors or CYP3A4 inducers.
  • History of seizure disorder.
  • Significant cardiovascular or cerebrovascular disease that, in the opinion of the investigator, would increase study risk.
  • Dementia-related psychosis.
  • Known hypersensitivity or allergy to lumateperone or any of its components.

Treatment and study plan

Lumateperone 42 mg

Drug

Lumateperone 42 mg orally daily

Primary outcomes

  1. MADRS

    Time frame: 6 week

    Montgomery Asperg Depression Rating Scale

  2. Inflammatory Markers

    Time frame: 6 weeks

    Tissue Necrosis factor alpha, C-reactive protein, Interleukins 1 beta, 6, 18

Study contacts

Contact information is provided by the study sponsor or research team.

Michael E Henry, MD

CONTACT

[email protected]

6176435759

Natalie Herbold, BS

CONTACT

[email protected]

6177248986

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • Johnson and Johnson Medical

Registry information

Official study title

The Effects of Lumateperone on Obesity and Physiologic Aging and Their Correlation With Antidepressant Response in Bipolar Depression

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jul 13, 2026
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.